Business Segments Scholar Rock Holding Corporation
Stocks
SRRK
US80706P1030
Biotechnology & Medical Research
|
Market Closed -
Nasdaq
01:30:00 29/08/2026 am IST
|
5-day change | 1st Jan Change | ||
| 57.80 USD | -2.46% |
|
+2.30% | +31.21% |
| 22/08 | Scholar Rock's Global Regulatory Path Further De-Risked, Wedbush Says | MT |
| 21/08 | Wedbush Adjusts Scholar Rock Price Target to $64 From $58, Maintains Outperform Rating | MT |
Sales 2025 by Business Segment
Sales 2025 by Geography
Historical Breakdown of Revenue by Business Segments
Net Income: Breakdown by Business Segment
Geographical Revenue Distribution History
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Biological Products | ||||||||||
Pharmaceuticals | 1.88Cr | 3.32Cr | - | - | - | |||||
Total Assets | 30Cr | 36Cr | 31Cr | 47Cr | 40Cr | |||||
Interest Expense | - | - | -65L | -68.37L | -68.93L | |||||
CAPEX | -52.48L | -10.64L | -71T | -98T | -6L | |||||
EBT | -13Cr | -13Cr | -17Cr | -25Cr | -38Cr | |||||
D&A | 26.27L | 29.86L | 28.44L | 19.37L | 16.58L | |||||
Operating Income | -13Cr | -13Cr | -17Cr | -25Cr | -38Cr | |||||
Net Income | -13Cr | -13Cr | -17Cr | -25Cr | -38Cr |
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
United States | 1.88Cr | 3.32Cr | - | - | - | |||||
Total Assets | 30Cr | 36Cr | 31Cr | 47Cr | 40Cr | |||||
Interest Expense | - | - | -65L | -68.37L | -68.93L | |||||
D&A | 26.27L | 29.86L | 28.44L | 19.37L | 16.58L | |||||
CAPEX | -52.48L | -10.64L | -71T | -98T | -6L | |||||
Net Income | -13Cr | -13Cr | -17Cr | -25Cr | -38Cr | |||||
EBT | -13Cr | -13Cr | -17Cr | -25Cr | -38Cr | |||||
Operating Income | -13Cr | -13Cr | -17Cr | -25Cr | -38Cr |
- Stock Market
- Stocks
- SRRK Stock
- Financials Scholar Rock Holding Corporation
- Business Segments
Select your edition
All financial news and data tailored to specific country editions
